title: Implication of androgen receptor in urinary bladder cancer: a critical mini review.
abstract: Cancer is probably the most dreaded disease of mankind and the bladder cancer is the fifth most common type of cancer worldwide. It is a major cause of cancer morbidity and mortality. From amongst the bladder cancer, the Transitional Cell Carcinoma (TCC) is the most prevalent cancer of the bladder and accounts for 90% of all bladder cancer cases. Despite such a high prevalence, the molecular mechanism involved in the induction of bladder carcinoma and its progression are poorly understood. Tumorigenesis and tumor progression of bladder carcinomas are thought to result from the accumulation of multiple genetic alterations. The Androgen Receptor (AR) gene is located on the q arm of X chromosome (q11-12) and considered as a ligand-inducible transcription factor that regulates target gene expression. The Androgen plays a vital role in the development and maintenance of the normal urinary bladder. The AR is also involved in the development and progression of urinary bladder carcinoma, which is the most common type of carcinoma. Mutation in AR alters the ligand binding ability that may cause the progression and development of bladder cancer. Tumorigenesis and tumor progression are thought to result from changes in the function of hormonal receptor gene. The accumulation of the changes in AR expressions, determines the tumor's phenotype and ultimately the patient's clinical outcome. The early detection of which may help in management and prediction, how will it behave and respond to the therapeutic regimen. The present review aimed to study the mechanism and alteration of AR gene that play a vital role in the tumorIgenesis of bladder carcinoma.
authors.affiliation: Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University Kingdom of Saudi Arabia.
authors.forename: Arshad H
authors.initials: AH
authors.lastname: Rahmani
authors.forename: Mohammad
authors.initials: M
authors.lastname: Alzohairy
authors.forename: Ali Yousif Y
authors.initials: AY
authors.lastname: Babiker
authors.forename: Amjad A
authors.initials: AA
authors.lastname: Khan
authors.forename: Salah M
authors.initials: SM
authors.lastname: Aly
authors.forename: Moshahid A
authors.initials: MA
authors.lastname: Rizvi
keywords: Androgen receptors; CAG repeat; DNA-binding domain; TCC; tumour progression
references.citation: Histopathology. 1997 Jun;30(6):556-62
references.pmid: 9205860
references.citation: Cancer Cell. 2004 Aug;6(2):111-6
references.pmid: 15324694
references.citation: Rev Urol. 2002 Spring;4(2):97-9
references.pmid: 16985663
references.citation: J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):135-42
references.pmid: 11384871
references.citation: J Biol Chem. 2001 Mar 9;276(10):7493-9
references.pmid: 11102454
references.citation: Steroids. 1996 Apr;61(4):205-11
references.pmid: 8733002
references.citation: N Engl J Med. 1995 May 25;332(21):1393-8
references.pmid: 7723794
references.citation: J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201
references.pmid: 12163131
references.citation: Essays Biochem. 2004;40:59-72
references.pmid: 15242339
references.citation: J Clin Oncol. 2002 Jul 1;20(13):3001-15
references.pmid: 12089231
references.citation: J Cell Biochem. 1993 Feb;51(2):140-50
references.pmid: 8440748
references.citation: Hum Mutat. 2004 Jun;23(6):527-33
references.pmid: 15146455
references.citation: Arch Ital Urol Androl. 2006 Sep;78(3):97-100
references.pmid: 17137023
references.citation: Urology. 2006 Mar;67(3 Suppl 1):11-7; discussion 17-8
references.pmid: 16530068
references.citation: BJU Int. 2011 Jul;108(1):24-30
references.pmid: 21070579
references.citation: Int J Biochem Cell Biol. 2007;39(7-8):1280-7
references.pmid: 17300979
references.citation: Mol Carcinog. 2011 Dec;50(12):931-44
references.pmid: 21400613
references.citation: Med Oncol. 2011 Dec;28(4):1520-6
references.pmid: 20652448
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Clin Cancer Res. 2001 May;7(5):1273-81
references.pmid: 11350894
references.citation: J Endocrinol. 1996 Oct;151(1):1-11
references.pmid: 8943763
references.citation: Urology. 2010 Apr;75(4):820-7
references.pmid: 20083299
references.citation: Nucleic Acids Res. 1998 Jan 1;26(1):234-8
references.pmid: 9399843
references.citation: J Cancer Res Clin Oncol. 2011 Aug;137(8):1255-62
references.pmid: 21698421
references.citation: Gynecol Endocrinol. 1999 Oct;13(5):327-32
references.pmid: 10599549
references.citation: Endocr Rev. 1995 Jun;16(3):271-321
references.pmid: 7671849
references.citation: Cancer. 2006 Jun 15;106(12):2610-6
references.pmid: 16700038
references.citation: J Clin Endocrinol Metab. 1993 Jan;76(1):17-23
references.pmid: 8421085
references.citation: Mol Cell Endocrinol. 2001 Jun 20;179(1-2):105-9
references.pmid: 11420135
references.citation: J Cancer Res Clin Oncol. 2012 Jan;138(1):103-9
references.pmid: 22033727
references.citation: Mol Endocrinol. 1997 Apr;11(4):450-9
references.pmid: 9092797
references.citation: J Endocrinol Invest. 1992 Nov;15(10):719-25
references.pmid: 1491120
references.citation: Gend Med. 2008 Dec;5(4):385-94
references.pmid: 19108811
references.citation: J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):443-8
references.pmid: 7626493
references.citation: Urology. 1985 Feb;25(2):161-3
references.pmid: 2578695
references.citation: N Engl J Med. 1994 Nov 10;331(19):1259-64
references.pmid: 7935683
references.citation: Int J Oncol. 2012 Jan;40(1):5-12
references.pmid: 21956088
references.citation: Endocr Relat Cancer. 2008 Mar;15(1):351-64
references.pmid: 18310301
references.citation: J Clin Endocrinol Metab. 2002 Jan;87(1):161-5
references.pmid: 11788641
references.citation: Int J Clin Exp Pathol. 2012;5(3):195-202
references.pmid: 22558473
references.citation: J Biol Chem. 2000 Aug 25;275(34):26164-71
references.pmid: 10840043
references.citation: Int J Clin Exp Med. 2013 Apr 12;6(4):239-51
references.pmid: 23641300
references.citation: Int J Clin Exp Pathol. 2012;5(9):965-71
references.pmid: 23119114
references.citation: Vitam Horm. 2005;71:301-19
references.pmid: 16112272
references.citation: Urology. 1986 Nov;28(5):401-3
references.pmid: 3787903
references.citation: Vitam Horm. 1995;51:315-38
references.pmid: 7483326
references.citation: Genes Dev. 2009 Mar 15;23(6):675-80
references.pmid: 19261747
references.citation: Mol Endocrinol. 1993 Dec;7(12):1541-50
references.pmid: 8145761
references.citation: Tumour Biol. 2012 Feb;33(1):17-22
references.pmid: 21931994
references.citation: BMC Urol. 2008 Apr 23;8:7
references.pmid: 18433501
references.citation: Pathol Oncol Res. 2011 Sep;17(3):579-86
references.pmid: 21221875
references.citation: J Natl Cancer Inst. 2007 Apr 4;99(7):558-68
references.pmid: 17406000
references.citation: Eur Urol. 2001 Sep;40(3):241-51
references.pmid: 11684838